USA flag logo/image

An Official Website of the United States Government

Antifibrotic Therapy for Chronic Kidney Disease

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96041
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
DK085841
Solicitation Year:
N/A
Solicitation Topic Code:
NIDDK
Solicitation Number:
N/A
Small Business Information
ANGION BIOMEDICA CORPORATION
51 Charles Lindbergh Blvd Uniondale, NY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Antifibrotic Therapy for Chronic Kidney Disease
Agency: HHS
Contract: 1R43DK085841-01A1
Award Amount: $271,934.00
 

Abstract:

DESCRIPTION (provided by applicant): Chronic kidney disease remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates renal replacement therapy. Few, if any, of the currently practiced therapeutic strategies oppose the molecular and cellular program of fibrosis that drives renal disease. For decades, Abl, c-KIT, PDGFR, KDR, and EGFR receptor tyrosine kinases have been implicated in growth factor signaling and angiogenesis. They have therefore been the targets for successful molecular targeted anti-neoplastic therapeutics. However, there is a substantial body of evidence that certain receptor tyrosine kinases, including PDGFR and KDR can also be promising target s for anti-fibrotic agents. While anti-neoplastic therapeutics have successfully been developed for use in oncology, it remains unclear whether these small molecules are suitable for use as antifibrotic agents. Angion Biomedica has identified ANG3154, a sm all molecule with PDGFR and KDR inhibitory activity. In experimental models of pulmonary and renal fibrosis, orally administered ANG3154 has exhibited powerful antifibrotic effects. Based on these compelling preliminary data, the present SBIR Phase I propo sal is designed to make an in-depth analysis of the antifibrotic effects of ANG3154 in experimental CKD. PUBLIC HEALTH RELEVANCE: A small molecule orally bioactive antifibrotic has significant clinical potential for treatment of chronic kidney disea se.

Principal Investigator:

Prakash Narayan
5163261200
PNARAYAN@ANGION.COM

Business Contact:

Itxhak D. Goldberg
igoldberg@angion.com
Small Business Information at Submission:

ANGION BIOMEDICA CORPORATION
ANGION BIOMEDICA CORP 1050 Stewart Ave. GARDEN CITY, NY 11530

EIN/Tax ID: 111343007
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No